This clinical trial is focused on studying the treatment of Giant Cell Arteritis (GCA), a condition that causes inflammation of the blood vessels, often leading to headaches, jaw pain, and vision problems. The study compares two treatments: Methotrexate (MTX), a medication commonly used to suppress the immune system, and Tocilizumab (TCZ), an injection that targets specific proteins involved in inflammation. Both treatments are being evaluated for their effectiveness over a period of 52 weeks.

The purpose of the study is to determine which treatment is more effective in managing GCA. Participants will receive either MTX or TCZ, along with a standard treatment of Prednisone, a type of steroid used to reduce inflammation. The study will monitor the participants’ health and response to the treatments over a total of 78 weeks, with regular follow-ups to assess their condition and any side effects.

Throughout the study, the focus will be on the percentage of patients who remain in remission, meaning their symptoms are under control, without experiencing a relapse. The study will also look at the quality of life of participants, their levels of tiredness, and any side effects they may experience. The ultimate goal is to find the most effective treatment strategy for managing Giant Cell Arteritis.